AR083546A1 - Tratamiento de inflamacion gastrointestinal, soriasis y asma - Google Patents

Tratamiento de inflamacion gastrointestinal, soriasis y asma

Info

Publication number
AR083546A1
AR083546A1 ARP110103933A ARP110103933A AR083546A1 AR 083546 A1 AR083546 A1 AR 083546A1 AR P110103933 A ARP110103933 A AR P110103933A AR P110103933 A ARP110103933 A AR P110103933A AR 083546 A1 AR083546 A1 AR 083546A1
Authority
AR
Argentina
Prior art keywords
antagonist
methods
gastrointestinal inflammation
provides
therapeutic agent
Prior art date
Application number
ARP110103933A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR083546A1 publication Critical patent/AR083546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente solicitud proporciona métodos y medios para reducir la inflamación gastrointestinal. En particular, la presente proporciona los métodos y medios para tratar la enfermedad inflamatoria intestinal (EII) y las afecciones relacionadas. La solicitud además proporciona los métodos y los medios para tratar la soriasis. La solicitud además proporciona los métodos y los medios para tratar el asma.Reivindicación 1: Un método para reducir la inflamación gastrointestinal, que comprende la administración a un sujeto que necesita al menos un antagonista de los receptores de la IL-17RA y la IL-17RE. Reivindicación 8: El método de la reivindicación 1 donde dicho antagonista es un anticuerpo o un fragmento de unión al antígeno del mismo. Reivindicación 10: El método de la reivindicación 1 que además comprende la administración de otro agente terapéutico para tratar la enfermedad inflamatoria intestinal. Reivindicación 11: El método de la reivindicación 10 donde dicho otro agente terapéutico es un antagonista IFN-g. Reivindicación 13: El método de la reivindicación 10 donde dicho otro agente terapéutico es un antagonista TNF-a. Reivindicación 34: Una composición farmacéutica que comprende un antagonista de IL-17RA y/o IL-17RE mezclado con un excipiente aceptable para uso farmacéutico para el tratamiento de la inflamación gastrointestinal.
ARP110103933A 2010-10-25 2011-10-25 Tratamiento de inflamacion gastrointestinal, soriasis y asma AR083546A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45578010P 2010-10-25 2010-10-25
US201161626838P 2011-10-03 2011-10-03
US201161627493P 2011-10-12 2011-10-12

Publications (1)

Publication Number Publication Date
AR083546A1 true AR083546A1 (es) 2013-03-06

Family

ID=44906468

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103933A AR083546A1 (es) 2010-10-25 2011-10-25 Tratamiento de inflamacion gastrointestinal, soriasis y asma

Country Status (5)

Country Link
US (1) US20120201821A1 (es)
EP (2) EP2633317A1 (es)
AR (1) AR083546A1 (es)
TW (1) TW201307385A (es)
WO (1) WO2012061129A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
LT2523688T (lt) 2010-01-15 2018-03-12 Kirin-Amgen, Inc. Antikūno kompozicija ir terapiniai režimai
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
SI2768859T1 (en) * 2011-10-19 2018-06-29 Morphosys Ag IL17C ANTAGONISTS FOR TREATMENT OF INFLAMATORY DISORDERS
US10308938B2 (en) 2014-06-20 2019-06-04 Yale University Compositions and methods to activate or inhibit toll-like receptor signaling
JP6944747B2 (ja) * 2014-12-15 2021-10-06 モルフォシス・アーゲー Ｉｌ−１７ｃに対する抗体
MX2018009860A (es) * 2016-02-19 2019-03-28 Morphosys Ag Anticuerpos para il-17c.
GB201803563D0 (en) * 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
CN112891531B (zh) * 2020-06-19 2021-10-08 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5527307A (en) 1994-04-01 1996-06-18 Minimed Inc. Implantable medication infusion pump with discharge side port
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5637095A (en) 1995-01-13 1997-06-10 Minimed Inc. Medication infusion pump with flexible drive plunger
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2064237A2 (en) * 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
US8460647B2 (en) * 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
KR101766927B1 (ko) 2009-04-01 2017-08-09 제넨테크, 인크. 인슐린 저항성 장애의 치료
SI2768859T1 (en) * 2011-10-19 2018-06-29 Morphosys Ag IL17C ANTAGONISTS FOR TREATMENT OF INFLAMATORY DISORDERS

Also Published As

Publication number Publication date
WO2012061129A1 (en) 2012-05-10
EP2633317A1 (en) 2013-09-04
TW201307385A (zh) 2013-02-16
EP3214442A1 (en) 2017-09-06
US20120201821A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
AR083546A1 (es) Tratamiento de inflamacion gastrointestinal, soriasis y asma
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
CL2012002536A1 (es) Composición farmacéutica que comprende un anticuerpo anti-factor de crecimiento nervioso (ngf) o un fragmento de unión al antígeno de éste, un amortiguador histidina 5 a 60mm, polisorbato 80 0,01% a 0,1%, y un ph entre 5,0 y 6,0; composición liofilizada; dispositivo; artículo de manufactura; y su uso en enfermedades mediadas por ngf, tales como trastornos del dolor.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
PE20190440A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
PE20080333A1 (es) Agentes para prevenir o tratar enfermedades inflamatorias
GT201200318A (es) Anticuerpos hacia gdf8 humano
ECSP11010827A (es) Citomegalovirus humano que neutraliza anticuerpos y su uso
ECSP088750A (es) Métodos y composiciones para antagonismo de rage
GT200600297A (es) Nuevos anticuerpos anti-madcam
BR112015021888A2 (pt) inibidores de dna-ik
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
GT200800269A (es) Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal